Are oncologists systematically overdosing cancer patients? The evidence is starting to suggest yes.

STAT News is examining whether cancer patients routinely receive more drug than they need to achieve therapeutic effect, raising questions about dose optimization in oncology. The piece sits within a broader conversation about how drug doses are set in clinical trials and whether those doses are carried forward into practice without sufficient scrutiny.

Why it matters

The question of whether cancer patients receive more drug than necessary is not new, but it is gaining traction in a way that feels different. The traditional approach to dose-finding in oncology trials was built around identifying the maximum tolerated dose, then treating that as the target. The logic made sense in an era when the goal was simply to find something that worked. The problem is that 'tolerated' and 'optimal' are not the same thing, and decades of practice have been built on that conflation.

The downstream effects are real and measurable: higher rates of toxicity, dose reductions in practice, treatment discontinuations, and a quality of life burden that rarely shows up in the survival curves used to justify approval. The FDA's Project Optimus is an attempt to reframe dose selection as a scientific question rather than a regulatory formality, but changing trial design norms takes time, and the existing formulary of approved drugs at approved doses is not going anywhere quickly. Clinicians working in oncology today are navigating that tension every time they write a prescription.

What to watch

Whether the FDA's Project Optimus initiative actually changes how sponsors design dose-finding studies, or whether it remains a guidance document with limited enforcement teeth.